Stereotactic Radiation Can Condense Treatment Times For Prostate Cancer Interview with:

Amar U. Kishan, MD Assistant Professor Department of Radiation Oncology University of California, Los Angeles

Dr. Kishan

Amar U. Kishan, MD
Assistant Professor
Department of Radiation Oncology
University of California, Los Angeles What is the background for this study? What are the main findings?

Response: Typical external beam radiation courses range up to 8-9 weeks in length (39-45 treatments). There are data that shorter courses, delivering a higher dose per day, may be just as effective.

Stereotactic body radiotherapy (SBRT) really pushes this concept by condensing the treatment to just four to five treatments, with a high dose per day.

Here, we present the pooled results of the outcomes of 2142 men with low and intermediate risk prostate cancer and a median of 6.9 years of followup.

We demonstrate a very favorable efficacy and safety profile. Specifically, the rates of recurrences were 4.5% and 10.2% for low and intermediate risk disease at 7 years, and rates of late severe toxicity were 2.4% for urinary toxicity and 0.4% for gastrointestinal toxicity. What should readers take away from your report?

Response: SBRT is a safe and effective treatment for low- and intermediate-risk prostate cancer. This suggests that it should be a standard of care option for patients. However, considerable care must be taken to do it safely (i.e., rigorous quality assurance, image guidance, etc.). What recommendations do you have for future research as a result of this work?

Response: SBRT is already being studied in randomized trials to establish that it should be the standard of care (singular) in low/intermediate risk disease. Interesting avenues of research involve examining SBRT in high-risk prostate cancer and in the postoperative setting.

Disclosures: I have received honoraria from Varian Medical Systems, Inc. and ViewRay, Inc. I have served on and Advisory Board for Janssen. 


Kishan AU, Dang A, Katz AJ, et al. Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer. JAMA Netw Open. 2019;2(2):e188006. doi:10.1001/jamanetworkopen.2018.8006

[wysija_form id=”3″]

Feb 12, 2019 @ 11:49 pm 


The information on is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.